MSD Animal Health Wins 2024 S&P Global Award for Best New Companion Animal Product for injectable formulation of BRAVECTO® (fluralaner)
Parasiticide Treatment for Dogs Offers Only Year-Round Flea and Tick Protection
Milton Keynes, U.K., 11th March, 2025 – MSD Animal Health, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), has received the S&P Global Animal Health 2024 Best New Companion Animal Product award for the injectable formulation of BRAVECTO® (fluralaner). It is the first and only parasiticide that protects dogs against fleas and ticks for an entire year with a single dose.
“Innovation lies at the heart of what we do at MSD Animal Health,” said Helene Lanz, Managing Director – UK & Ireland, MSD Animal Health. “In a market historically led by monthly and three monthly products, it’s fantastic to have our company’s commitment to delivering solutions that shape the industry and give veterinarians and pet owners more flea and tick prevention options recognised.”
The injectable formulation of BRAVECTO was first approved in Australia and New Zealand in 2023, followed by the European Union and Great Britain in 2024. In total, the injectable formulation of BRAVECTO is currently approved in more than 30 countries worldwide.
S&P Global is a market intelligence company. The S&P Global Animal Health 2024 Best New Companion Animal Product award was presented at the Animal Health, Nutrition, Technology and Innovation Europe conference held in London on 11th February 2025.
“MSD Animal Health has continued to bring differentiated products like this novel injectable formulation to the market,” said Joseph Harvey, head of S&P Global Animal Health. “The company continues to build its reputation by winning awards in both Companion Animal and Food Animal categories over many years, which is a testament to its innovation and customer focus within the industry.”
This award marks the second time that the company is honored in this category. In 2015, the company won Best Product Pipeline and Best New Companion Animal Product for the Canine Influenza Vaccine H3N2. Previously, the company has won for the sixth straight year in the Best New Food Animals category for the IDAL® portfolio technology, PORCILIS® Lawsonia intramuscular vaccine for piglets, NOBILIS® SALENVAC ETC, WHISPER® ON ARRIVAL, SENSEHUB® Feedlot and CIRCUMVENT® CML. Additionally, MSD Animal Health was named Best Animal Health Company, North America in 2021, and Best Visionary CEO for Rick DeLuca in 2020.
###
About MSD Animal Health
At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and X (formerly Twitter).
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
###